Abstract:Emerging and recurrent infectious diseases caused by coronaviruses remain a significant public health concern. Here, we present a targeted approach to elicit antibodies capable of neutralizing SARS-CoV-2 variants and other SARS-related coronaviruses. By introducing amino acid mutations at mutation-prone sites, we engineered glycosylation modifications to the Receptor Binding Domain (RBD) of SARS-CoV-2, thereby exposing more conserved, yet less accessible epitopes. We developed both messenger RNA (mRNA) and recombination subunit vaccines using these engineered-RBDs (M1, M2) and the wild-type RBD as immunogens. The engineered-RBD vaccines elicited robust neutralizing responses against various SARS-CoV-2 variants as well as SARS-CoV and WIV1-CoV, and conferred protection in mice challenged with the XBB.1.16 strain. Furthermore, We highlighted that glycan masking is a decisive factor in antibody binding changes and RBD-conserved antibody response. Additionally, the glycan-engineered RBD mRNA vaccines stimulated stronger cell-mediated immune responses. Our glycan modification strategy significantly enhances broad-spectrum neutralizing efficacy and cellular immunity, providing valuable insights for the development of vaccines against a wide range of SARS-related coronaviruses. Since late 2020, numerous SARS-CoV-2 variants have emerged across different regions, with the Omicron variant and its subvariants (e.g., BA.5, XBB, JN.1, etc.) posing significant challenges to ongoing efforts in controlling the pandemic. This highlights the urgent need for broadly protective vaccines that target both SARS-CoV-2 variants and other SARS-related coronaviruses that could cause future outbreaks. In this study, we developed a glycan modification strategy based on N-glycosylation by introducing amino acid mutations in the RBD. Using these engineered RBDs (M1, M2) and wild-type RBD as immunogens, we created thermostable mRNA vaccines and recombinant subunit vaccines. Our results demonstrate that these engineered-RBD vaccines elicit potent neutralizing responses against notonly various SARS-CoV-2 variants, but also other coronaviruses like SARS-CoV and WIV1-CoV, surpassing the immune response triggered by the wild-type RBD. Furthermore, glycan-engineered RBD mRNA vaccines stimulated stronger cell-mediated immune responses and provided effective protection against XBB strain challenge in mice. We identified key glycosylation modifications at residues K417, L452, R457, and Q493 that play a critical role in inducing broad-spectrum neutralizing antibodies. In particular, the glycosylation of residues R457 and Q493 was especially effective in enhancing this immune response. These findings offer valuable insights for the design of broad-spectrum vaccines against SARS-related coronaviruses.

Major role of S-glycoprotein in providing immunogenicity and protective immunity in mRNA lipid nanoparticle vaccines based on SARS-CoV-2 structural proteins

Major Role of S-Glycoprotein in Providing Immunogenicity and Protective Immunity in mRNA Lipid Nanoparticle Vaccines Based on SARS-CoV-2 Structural Proteins

Structural and biochemical characteristics of mRNA nanoparticles determine anti-SARS-CoV-2 humoral and cellular immune responses

A Single Immunization with Nucleoside-Modified mRNA Vaccines Elicits Strong Cellular and Humoral Immune Responses against SARS-CoV-2 in Mice

Durable cross-protective neutralizing antibody responses elicited by lipid nanoparticle-formulated SARS-CoV-2 mRNA vaccines

Modulating the immune response to SARS-CoV-2 by different nanocarriers delivering an mRNA expressing trimeric RBD of the spike protein: COVARNA Consortium

Innate and Adaptive Immune Parameters following mRNA Vaccination in Mice

Computationally designed mRNA-launched protein nanoparticle vaccines

Adjuvant lipidoid-substituted lipid nanoparticles augment the immunogenicity of SARS-CoV-2 mRNA vaccines

In Silico Design of a Trans-Amplifying RNA-Based Vaccine against SARS-CoV-2 Structural Proteins

Dual spike and nucleocapsid mRNA vaccination confer protection against SARS-CoV-2 Omicron and Delta variants in preclinical models

Domain-based mRNA vaccines encoding spike protein N-terminal and receptor binding domains confer protection against SARS-CoV-2

Directing an mRNA-LNP vaccine toward lymph nodes improves humoral and cellular immunity against SARS-CoV-2

Virus-like structures for combination antigen protein mRNA vaccination

Lipid nanoparticles enhance the efficacy of mRNA and protein subunit vaccines by inducing robust T follicular helper cell and humoral responses

Study of the Effects of Several SARS-CoV-2 Structural Proteins on Antiviral Immunity

Broad protection and respiratory immunity of dual mRNA vaccination against SARS-CoV-2 variants

An inoculation site-retained mRNA vaccine induces robust immune responses against SARS-CoV-2 variants

Heterologous mRNA/MVA delivering trimeric-RBD as effective vaccination regimen against SARS-CoV-2: COVARNA Consortium

Development of Glycan-masked SARS-CoV-2 RBD vaccines against SARS-related coronaviruses

Hybrid Proteins with Short Conformational Epitopes of the Receptor-Binding Domain of SARS-CoV-2 Spike Protein Promote Production of Virus-Neutralizing Antibodies When Used for Immunization